RegulatoryEconomic Times
Aurobindo Pharma arm gets 'Voluntary Action Indicated' classification for Telengana facility from USFDA
Negative-35
GreyOak summary
Aurobindo Pharma's subsidiary, Apitoria Pharma, received a Voluntary Action Indicated (VAI) classification from the US FDA. This follows an inspection of its Telangana API facility conducted between September 7 and 15, 2026. The classification indicates objectionable conditions were observed, requiring the company to voluntarily implement corrective measures.
What it affects
- Aurobindo PharmaAUROPHARMANegative -35
USFDA inspection led to VAI classification.Rolling sentiment Negative -25
Source
Read the original at Economic TimesMore Aurobindo Pharma news
- Aurobindo Pharma shares extend losses after USFDA OAICNBC-TV18 · Regulatory ·
- USFDA classifies Aurobindo Pharma's US facility as 'official action indicated'Economic Times · Regulatory ·
- Aurobindo Pharma snaps 12-day winning streak after USFDA update on subsidiary's API unitCNBC-TV18 · Regulatory ·
- Helios Mid Cap Fund adds Aurobindo Pharma, increases stake in PaytmEconomic Times · Company update ·